- Home
- TAK vs A Comparison
TAK vs A Comparison
Compare TAK & A Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAK
- A
- Stock Information
- Founded
- TAK 1781
- A 1999
- Country
- TAK Japan
- A United States
- Employees
- TAK N/A
- A N/A
- Industry
- TAK Biotechnology: Pharmaceutical Preparations
- A Biotechnology: Laboratory Analytical Instruments
- Sector
- TAK Health Care
- A Industrials
- Exchange
- TAK Nasdaq
- A Nasdaq
- Market Cap
- TAK 42.2B
- A 38.6B
- IPO Year
- TAK N/A
- A 1999
- Fundamental
- Price
- TAK $14.07
- A $135.35
- Analyst Decision
- TAK
- A Buy
- Analyst Count
- TAK 0
- A 15
- Target Price
- TAK N/A
- A $142.64
- AVG Volume (30 Days)
- TAK 1.8M
- A 1.6M
- Earning Date
- TAK 01-30-2025
- A 02-26-2025
- Dividend Yield
- TAK 3.63%
- A 0.73%
- EPS Growth
- TAK 15.39
- A 5.73
- EPS
- TAK 0.83
- A 4.43
- Revenue
- TAK $29,124,927,177.00
- A $6,510,000,000.00
- Revenue This Year
- TAK $7.80
- A $7.05
- Revenue Next Year
- TAK $0.36
- A $6.43
- P/E Ratio
- TAK $33.80
- A $30.56
- Revenue Growth
- TAK 9.83
- A N/A
- 52 Week Low
- TAK $12.58
- A $124.16
- 52 Week High
- TAK $15.08
- A $155.35
- Technical
- Relative Strength Index (RSI)
- TAK 64.16
- A 35.14
- Support Level
- TAK $13.66
- A $133.94
- Resistance Level
- TAK $13.97
- A $138.58
- Average True Range (ATR)
- TAK 0.13
- A 2.90
- MACD
- TAK 0.06
- A -1.44
- Stochastic Oscillator
- TAK 96.15
- A 8.61
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
About A Agilent Technologies Inc.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.